✦ LIBER ✦

Lapatinib and HER2 status: Results of a meta-analysis of randomized phase III trials in metastatic breast cancer

✍ Scribed by Eitan Amir; Alberto Ocaña; Bostjan Seruga; Orit Freedman; Mark Clemons

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bevacizumab in metastatic breast cancer:

✍ A. Valachis; N. P. Polyzos; N. Α. Patsopoulos; V. Georgoulias; D. Mavroudis; D. 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 360 KB

Prognostic and Predictive Value of HER2

✍ Gilcrease, M.Z. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 87 KB

Adjuvant Trastuzumab Therapy In Her2-Pos

✍ Xia, Y.; Bian, B.; Costea, E.; Kelton, C.M.; Guo, J.J. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

A phase II study of lapatinib and bevaci

✍ Hope S. Rugo, A. Jo Chien, Sandra X. Franco, Alison T. Stopeck, Alexa Glencer, S 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 271 KB

Exemestane Improves Survival in Metastat

✍ Manfred Kaufmann; Emilio Bajetta; Luc Yves Dirix; Luis Enrique Fein; Stephen E. 📂 Article 📅 2000 🏛 CIG Media Group, LP. 🌐 English ⚖ 102 KB

Meta-analysis of phase III trials of doc

✍ Maurizio Belfiglio; Caterina Fanizza; Nicola Tinari; Corrado Ficorella; Stefano 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 627 KB